Nanocovax
- Generic Name
- Nanocovax
Study to Evaluate the Safety, Immunogenicity, and Efficacy of Nanocovax Vaccine Against COVID-19
Phase 3
Completed
- Conditions
- SARS-CoV-2 InfectionCOVID-19
- Interventions
- Biological: Placebo
- First Posted Date
- 2021-06-11
- Last Posted Date
- 2025-03-27
- Target Recruit Count
- 13006
- Registration Number
- NCT04922788
- Locations
- 🇻🇳
Military Medical Academy, Hanoi, Vietnam
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath